Cargando…

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease

Background: In the advanced stages of Parkinson’s disease (APD), complex forms of dyskinesia may severely impair the patient’s quality of life. Objective: In the present study, we aimed to analyze the evolution under LCIG therapy of the most important motor fluctuations and complex disabling dyskine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szász, József Attila, Constantin, Viorelia Adelina, Orbán-Kis, Károly, Bancu, Ligia Ariana, Ciorba, Marius, Mihály, István, Nagy, Előd Ernő, Szász, Róbert Máté, Kelemen, Krisztina, Simu, Mihaela Adriana, Szatmári, Szabolcs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301838/ https://www.ncbi.nlm.nih.gov/pubmed/34206596 http://dx.doi.org/10.3390/brainsci11070826

Ejemplares similares

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Observations and Dilemmas after 10 Years of Real-Life Experience
por: Szász, József Attila, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin, Viorelia Adelina, et al.
Publicado: (2020)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
por: Szász, József Attila, et al.
Publicado: (2019)

Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis
por: Simu, Mihaela Adriana, et al.
Publicado: (2021)

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
por: Szász, József Attila, et al.
Publicado: (2019)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

A Rare Case of Histopathologically Confirmed Creutzfeldt–Jakob Disease from Romania, Long Route to Diagnosis—Case Report and an Overview of the Romanian CJD Situation
por: Kelemen, Krisztina, et al.
Publicado: (2022)

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
por: Freire‐Alvarez, Eric, et al.
Publicado: (2021)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study
por: Fasano, Alfonso, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
por: Cruse, Belinda, et al.
Publicado: (2018)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Parkinson’s disease: carbidopa, nausea, and dyskinesia
por: Hinz, Marty, et al.
Publicado: (2014)

Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS
por: Fasano, Alfonso, et al.
Publicado: (2023)

Xanthonychia Due to Staining From Carbidopa-Levodopa
por: Hwang, Jonathan Kyle, et al.
Publicado: (2023)

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
por: Oshiro, Saki, et al.
Publicado: (2021)

Neuroinflammation and microglia/macrophage phenotype modulate the molecular background of post-stroke depression: A literature review
por: Nagy, Előd Ernő, et al.
Publicado: (2020)

Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Retraction]
Publicado: (2021)

Membranous nephropathy associated with the use of levodopa-carbidopa combination
por: Chaitanya, V., et al.
Publicado: (2015)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
por: Vijiaratnam, Nirosen, et al.
Publicado: (2017)

Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens
por: Thomson, Kate, et al.
Publicado: (2021)

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
por: Chaudhuri, K. Ray, et al.
Publicado: (2023)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern]
Publicado: (2020)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
por: Kovács, Norbert, et al.
Publicado: (2022)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oug4elu4br0enu9ii309hgvpuu